Home Institutions Yale clinical trials Institution Directory
Clinical trials at Yale Sites in New Haven, CT
Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.
ClinicalTrials.gov public records Last synced Nov 3, 2026, 8:05 AM EST
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1245
Current sort
Recently updated
Campus scope
Yale, New Haven, CT
Additional filters apply within this campus.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 1117–1128 of 1,245 matching trials with a site at Yale, New Haven, CT.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.
Live official records
Conditions ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions Clinical Observation, Crizotinib, Laboratory Biomarker Analysis Other · Drug
Lead sponsor ECOG-ACRIN Cancer Research Group Network
Eligibility 18 Years and older
Enrollment 166 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2015 – 2036
U.S. locations 1613
States / cities Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 978 more
Conditions Von Willebrand Diseases
Interventions Use of a postpartum diary and additional blood draws., VWF replacement therapy with Wilate, Tranexamic acid Other · Drug
Lead sponsor University of Washington Other
Eligibility 18 Years and older · Female only
Enrollment 110 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2019 – 2026
U.S. locations 11
States / cities Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 8 more
Conditions Metastatic Prostate Cancer, Prostate Adenocarcinoma
Interventions Cabozantinib, Atezolizumab, Abiraterone Acetate, Enzalutamide, Prednisone Drug
Lead sponsor Exelixis Industry
Eligibility 18 Years and older · Male only
Enrollment 575 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2020 – 2026
U.S. locations 36
States / cities Tucson, Arizona • Duarte, California • Fullerton, California + 30 more
Conditions Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Interventions Tarlatamab, Durvalumab Drug
Lead sponsor Amgen Industry
Eligibility 18 Years to 99 Years
Enrollment 563 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2024 – 2028
U.S. locations 37
States / cities Mobile, Alabama • Los Angeles, California • New Haven, Connecticut + 32 more
Conditions GIST
Interventions Ripretinib, Sunitinib Drug
Lead sponsor Deciphera Pharmaceuticals, LLC Industry
Eligibility 18 Years and older
Enrollment 54 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2023 – 2028
U.S. locations 20
States / cities La Jolla, California • New Haven, Connecticut • Jacksonville, Florida + 15 more
Conditions Aortic Stenosis, Calcific, Aortic Valve Stenosis
Interventions SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Device
Lead sponsor Edwards Lifesciences Industry
Eligibility 65 Years and older
Enrollment 2,250 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2021 – 2037
U.S. locations 65
States / cities Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 52 more
Conditions E-cigarette Use, Vaping, Nicotine Dependence
Interventions Varenicline 1mg BID, Placebo Drug
Lead sponsor Yale University Other
Eligibility 18 Years and older
Enrollment 326 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2025 – 2030
U.S. locations 2
States / cities New Haven, Connecticut • Charleston, South Carolina
Conditions Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
Interventions Capecitabine, Temozolomide Drug
Lead sponsor SWOG Cancer Research Network Network
Eligibility 18 Years and older
Enrollment 141 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2022 – 2027
U.S. locations 446
States / cities Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 300 more
Conditions Unresectable Metastatic Colorectal Cancer
Interventions ABBV-400, Bevacizumab, Folinic Acid, Fluorouracil, Irinotecan Drug
Lead sponsor AbbVie Industry
Eligibility 18 Years and older
Enrollment 280 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2023 – 2026
U.S. locations 22
States / cities Phoenix, Arizona • Springdale, Arkansas • Duarte, California + 15 more
Conditions Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions Biospecimen Collection, Cognitive Assessment, Dietary Intervention, Medical Device Usage and Evaluation, Questionnaire Administration Procedure · Other
Lead sponsor Ohio State University Comprehensive Cancer Center Other
Eligibility 40 Years to 65 Years · Female only
Enrollment 60 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2024 – 2026
U.S. locations 2
States / cities New Haven, Connecticut • Columbus, Ohio
Conditions Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation, Complete Response, Partial Response, First Line Platinum Chemotherapy
Interventions Olaparib 300mg tablets Drug
Lead sponsor AstraZeneca Industry
Eligibility 18 Years to 130 Years · Female only
Enrollment 450 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2013 – 2028
U.S. locations 81
States / cities Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 63 more
Conditions Advanced Solid Tumor
Interventions FT825, Fludarabine, Cyclophosphamide, Bendamustine, Docetaxel, Cisplatin, Cetuximab Drug
Lead sponsor Fate Therapeutics Industry
Eligibility 18 Years and older
Enrollment 351 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2024 – 2044
U.S. locations 14
States / cities Gilbert, Arizona • La Jolla, California • New Haven, Connecticut + 11 more About this Yale institution page
What this page lists ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.
Related: all institution pages , trials led by Yale University at any site , browse by condition , or browse by U.S. city .